The medical device development ecosystem: Current regulatory state and challenges for future development: A review

Area of Science:

• Cardiovascular medicine
• Medical device development
• Regulatory science

Background:

• Increasing emphasis on developing new technologies for unmet clinical needs in cardiovascular disease.
• Many medical devices, initially developed in the U.S., faced delays in clinical application due to foreign study and approval processes.
• The Food and Drug Administration (FDA) guidance on Early Feasibility Studies (EFS) and the 21st Century Cures Act addressed these translational pathway issues.

Purpose of the Study:

• To review the multifaceted components of medical device translational pathways.
• To document the stages from initial innovation to clinical application of cardiovascular devices.
• To highlight efforts to provide earlier access to safe and effective medical products in the U.S.

Main Methods:

• Documented the stages of medical device development, from idea to clinical practice.
• Reviewed regulatory initiatives and programs aimed at improving the device development ecosystem.
• Analyzed the impact of FDA-focused components on medical device innovation.

Main Results:

• The Centers for Devices and Radiological Health (CDRH) has implemented key initiatives: Early Feasibility Studies (EFS), Breakthrough Devices Program, Total Product Life Cycle, Unique Device Identification Program, Digital Health Center of Excellence, and Collaborative Communities.
• These initiatives collectively aim to enhance the Medical Device Development Ecosystem.
• Significant improvements in the U.S. device research climate have been observed.

Conclusions:

• Major advancements in device translational research have positively impacted the U.S. research environment.
• Continued focus on training and education is crucial for aspiring professionals in device development and regulation.
• The goal is to foster a continuous learning system within healthcare for device innovation.